Дізнайтеся про найкращі ціни та клініки з лікування апластичної анемії у Італії у 2026 році

Standard care for aplastic anemia in Italy prioritizes allogeneic bone marrow transplantation for younger patients with matched donors. Leading Italian centers like San Raffaele utilize immunosuppressive therapy with horse antithymocyte globulin and cyclosporine for older patients. These facilities maintain IRCCS accreditation to combine advanced research with clinical practice.

• First-line therapy: Allogeneic bone marrow transplantation from a related or unrelated donor.
• Immunosuppression protocol: Combinations of horse antithymocyte globulin, cyclosporine, and eltrombopag for non-transplant candidates.
• Advanced diagnostics: Bone marrow biopsy and cytogenetic studies guide precise treatment selection.
• Specialized supervision: Centers like San Raffaele integrate hematologists and transplant surgeons for care.

Bookimed Expert Insight: Italian centers like San Raffaele distinguish themselves by integrating cell and gene therapy research directly into hematology departments. Professor Fabio Ciceri at San Raffaele has over 20 years of experience leading bone marrow units. This research-heavy focus provides patients with early access to emerging protocols and specialized care for rare genetic immune disorders.

Patient Consensus: Patients note it is important to confirm if a facility provides both immunosuppression and full transplant options. They emphasize that specialized hematology centers are necessary for managing this complex condition effectively.

Italian centers secure patient safety through precise donor screening and non-irradiation conditioning protocols. Facilities like San Raffaele utilize ATG and Cyclophosphamide to lower cancer risks. High-dose chemotherapy prepares the marrow while strict isolation protocols and antibacterial prophylaxis prevent post-transplant infections.

• Donor assessment: Rigorous cardiac and renal testing ensures high-quality stem cell grafts.
• Conditioning regimens: Non-irradiation methods reduce the risk of secondary solid-organ cancers.
• GvHD prevention: Use of Post-transplant Cyclophosphamide (PTCy) helps prevent graft-versus-host disease.
• Infection control: HEPA-filtered isolation and prophylactic antivirals minimize environmental pathogen exposure.

Bookimed Expert Insight: San Raffaele in Milan stands out because it integrates laboratory research directly with patient care. This IRCCS-accredited facility performed the world’s first stem cell therapy for severe immune deficiency. This deep expertise in cell engineering allows their hematologists to manage complex aplastic anemia cases that require specialized graft manipulation.

Patient Consensus: Patients note that Italian centers provide faster access to public donor registries. They emphasize that daily bloodwork and weekly PCR monitoring for viral reactivation provide a vital safety net during recovery.

The ideal international candidate for aplastic anemia treatment in Italy is typically under 40 years old. Patients with severe (SAA) or very severe (vSAA) classifications prioritize curative bone marrow transplants. Those with a human leukocyte antigen (HLA) identical sibling donor achieve the most successful outcomes in Italian hematology centers.

• Age criteria: Patients under 40 years see higher survival and fewer transplant-related complications.
• Clinical status: Ideal candidates maintain a performance status above 70% on the Karnofsky scale.
• Donor match: Having an HLA-matched sibling remains the gold standard for immediate treatment availability.
• Alternative options: Italian specialists successfully treat patients using haploidentical or unrelated donor matches.

Bookimed Expert Insight: San Raffaele Hospital in Milan is a global leader, performing over 52,000 annual operations and 1,000 bone marrow transplants. Professor Fabio Ciceri specializes in cellular therapies, having published 180 scientific papers on gene and stem cell therapy. While adults over 50 may face stricter eligibility, pediatric patients benefit from Italy's specialized research-driven protocols. Candidates with private insurance often find Milan's accredited facilities more accessible than regional public centers.

Patient Consensus: Patients note that arriving with a ready donor significantly speeds up the process. Those from outside the EU emphasize that private insurance is vital for securing a slot.

Medical tourists should plan for an 8 to 12 week stay in Italy for immunosuppressive therapy. Initial hospitalization for anti-thymocyte globulin lasts 5 to 14 days. Patients must remain nearby for 2 months post-discharge to monitor blood counts and manage potential complications like infection or cytomegalovirus reactivation.

• Initial observation: Centers in Milan suggest 14 days for immediate post-infusion side effect management.
• Monitoring frequency: Weekly bloodwork and cyclosporine level checks are mandatory for 3 to 6 months.
• Response evaluation: Bone marrow biopsies occur at 3, 6, and 12 months to track progress.
• Long-term tapering: Cyclosporine doses gradually decrease by 25% every 3 months over 18 months.
• Annual screenings: Yearly bone marrow morphology tests monitor for potential late-stage clonal diseases.

Bookimed Expert Insight: Italian research hospitals like San Raffaele specialize in complex hematology and perform over 52,000 operations annually. Data shows that while the initial hospital stay may be short, patients often face 4 to 6 weeks of intense inpatient care during the induction phase. Choosing a center in Milan allows access to specialists like Prof. Dr. Fabio Ciceri, who leads major clinical trials in gene and cell therapy.

Patient Consensus: Patients emphasize the need to plan for stay extensions as recovery often takes twice as long as expected. Many recommend setting up telemedicine links with Italian doctors to manage long-term follow-ups once they return home.

Patients undergoing allogeneic transplants in Italy typically experience short-term mucositis and bone marrow suppression within 100 days. Long-term risks include chronic graft-versus-host disease (GVHD) affecting 30% to 50% of recipients. Italian centers like San Raffaele utilize advanced donor matching to manage these complications.

• Mucositis: Painful mouth and throat sores often occur during the initial conditioning phase.
• Bone marrow suppression: Low blood counts increase risks of infections and fatigue early on.
• Acute GVHD: Donor cells may attack skin or liver within 100 days post-transplant.
• Chronic GVHD: This condition may cause skin tightening or lung scarring years later.
• Endocrine issues: Infertility and thyroid dysfunction are common long-term effects of chemotherapy regimens.

Bookimed Expert Insight: Italian academic centers like San Raffaele concentrate high volumes of rare cases, performing over 52,000 operations annually. This clinical density allows specialists like Professor Fabio Ciceri to manage complex engraftment delays more effectively than smaller regional clinics. Data shows these high-volume settings are crucial for patients requiring specific cell and gene therapy trials.

Patient Consensus: Patients emphasize that severe mouth sores are the most difficult immediate challenge. Many suggest bringing a reliable translation app to navigate isolation protocols during long stays in Italian hospitals.

Milan and Rome are Italy's primary destinations for aplastic anemia treatment. Leading centers like San Raffaele and Agostino Gemelli hold Joint Commission International (JCI) and JACIE accreditations. These facilities offer advanced allogeneic bone marrow transplants. Italian institutions specialize in complex donor matching and regenerative cell therapies.

• Milan medical hub: San Raffaele performs over 140 transplants yearly with IRCCS research accreditation.
• Rome university clinicals: Agostino Gemelli University Policlinic is JCI-accredited and a top-ranked European hospital.
• JACIE-certified programs: San Camillo Forlanini and Bologna's Policlinico S. Orsola-Malpighi maintain rigorous transplant standards.
• Specialized pediatric care: Notable regional centers in Bologna and Monza offer dedicated pediatric stem cell units.

Bookimed Expert Insight: Milan serves as the strategic gateway for international hematology cases due to high patient volume. San Raffaele alone treats 300,000 patients annually and performs 52,000 operations. Professor Dr. Fabio Ciceri leads their unit with specialized training from Memorial Sloan Kettering. This concentration of expertise makes Milan ideal for rare blood disorders requiring complex gene therapies.

Patient Consensus: Patients note that Milan and Rome offer the best logistic support and translator services. Many emphasize securing EU health referrals early to manage wait times at these high-reputation centers.

Italy does not have a formal waiting list for unrelated donor hematopoietic stem cell transplants. Instead, the search for a matched donor typically takes between a few weeks and six months depending on genetic complexity. Italian centers like San Raffaele utilize international registries to identify compatible matches efficiently.

• Search duration: Identifying an unrelated donor often takes 30 days to several months.
• Registry access: Centers access the Italian Bone Marrow Donor Registry and international databases.
• HLA matching: Common genetic profiles find matches faster than rare human leukocyte antigen types.
• Clinical priority: Patients non-responsive to immunosuppressive therapy receive standard unrelated donor searches.
• Alternative options: Doctors may utilize haploidentical donors if an unrelated match is not found.

Bookimed Expert Insight: Data shows centers like San Raffaele in Milan combine research with clinical care as IRCCS-accredited institutions. Dr. Fabio Ciceri leads specialized units that manage rare immune diseases and complex genetic screenings. This infrastructure allows for rapid transition from diagnosis to transplant once a donor is secured. Patients should choose centers with high operation volumes, as San Raffaele performs over 52,000 surgeries yearly.

Patient Consensus: Patients note that flagging a case as urgent can significantly reduce search timelines. They also suggest having a family member ready for a haploidentical transplant as a reliable backup plan.